CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Regulation FD Disclosure
Item 7.01.
|
Regulation FD Disclosure. |
Attached as Exhibit 99.1 to this Current Report on Form 8-K is an
updated investor presentation that Cesca Therapeutics Inc. (the
Company) may use in presentations to investors from time to time.
The information in this Item 7.01 shall not be treated as filed
for purposes of the Securities Exchange Act of 1934, as amended.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Investor Presentation (May 2017). |
About CESCA THERAPEUTICS INC. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood. CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Recent Trading Information
CESCA THERAPEUTICS INC. (NASDAQ:KOOL) closed its last trading session up +0.05 at 3.19 with 14,814 shares trading hands.
